Cialis (Tadalafil) Evidence Base Graded by GRADE

What Is the GRADE Certainty Level for Tadalafil in Erectile Dysfunction?

Tadalafil on-demand (10 mg and 20 mg) receives a HIGH GRADE certainty rating for erectile dysfunction. This rating reflects multiple large, well-designed, double-blind RCTs with consistent directional effects, low risk of bias, and precise estimates that do not cross the null. The evidence base spans more than 10,000 patient-trial-years and includes dose-finding, maintenance, and withdrawal designs.

How GRADE Applies to PDE5 Inhibitor Trials

GRADE evaluates five factors that can lower certainty (risk of bias, inconsistency, indirectness, imprecision, publication bias) and three that can raise it (large effect size, dose-response relationship, residual confounding working against the effect) [1]. Tadalafil trials score well on all five downgrade criteria: allocation concealment was adequate in key studies, outcomes were validated (the IIEF-EF domain is a patient-reported outcome accepted by FDA and EMA), effects are consistent across subgroups, confidence intervals are narrow, and a clear dose-response relationship exists between 5 mg, 10 mg, and 20 mg [2].

Core Efficacy Figures from Key RCTs

In the registration program supporting FDA approval, tadalafil 20 mg produced IIEF-EF domain scores 7.9 points higher than placebo at 12 weeks (baseline-adjusted mean difference, P<0.001) [2]. Successful intercourse rates reached 75% with tadalafil 20 mg versus 32% with placebo across pooled phase III data [3]. A Cochrane systematic review of PDE5 inhibitors (Qaseem et al. Framework, 151 trials, N>17,000) confirmed that all licensed PDE5 inhibitors, including tadalafil, produced clinically meaningful IIEF-EF improvements compared with placebo, with no statistically significant difference in efficacy between agents at licensed doses [4].

The 36-Hour Window and Patient-Reported Outcomes

Tadalafil's 17.5-hour half-life produces a clinical action window of approximately 36 hours, which distinguishes it from sildenafil (4-6 hours) and vardenafil (4-5 hours) [5]. In a crossover preference study (Brock et al., J Urol 2002, N=181 men who had previously used sildenafil), 71% of participants preferred tadalafil, citing the longer window as the primary reason [6]. Mean erection duration with tadalafil 20 mg was also numerically longer than with sildenafil 50 mg in that same crossover design [6]. These patient-reported preference data upgrade the practical relevance of the efficacy evidence without altering the GRADE certainty level itself.

Daily 5 mg Tadalafil for ED: GRADE Certainty and Key Numbers

Daily tadalafil 5 mg earns a MODERATE GRADE certainty rating for ED, one step below on-demand dosing because the daily-dosing trial database, while substantial, contains fewer enrolled patients than the on-demand dataset and has less long-term (beyond 12 months) controlled data.

Randomized Evidence Supporting Daily Dosing

The key daily-dosing ED trials pooled in the FDA submission (total N=1,054 across three studies, 12 weeks each) showed IIEF-EF domain improvements of 5.8 points over placebo for tadalafil 5 mg and 6.4 points for tadalafil 10 mg once daily [7]. Successful intercourse rates were 64% with tadalafil 5 mg once daily versus 36% with placebo (P<0.001) [7]. One extension study followed participants for 24 months and found no attenuation of effect, supporting durability, but it lacked a concurrent placebo arm after week 12 [8].

Endothelial and Penile Rehabilitation Considerations

Daily low-dose tadalafil may improve endothelial function independently of sexual activity. A 12-week RCT in men with type 2 diabetes (N=112) showed flow-mediated dilation increased by 2.1% in the tadalafil 5 mg group versus 0.4% in placebo (P=0.03) [9]. Some post-prostatectomy rehabilitation protocols use daily tadalafil on this basis, though GRADE certainty for the rehabilitation indication specifically remains LOW given small trial sizes and heterogeneous surgical techniques [10].

Tadalafil for BPH-Associated Lower Urinary Tract Symptoms: GRADE Evidence

The FDA granted tadalafil 5 mg once daily approval for signs and symptoms of BPH in 2011, making it the only PDE5 inhibitor with this labeled indication [11]. GRADE certainty for this indication is MODERATE, driven by consistent short-term RCT evidence but limited data beyond 12 weeks and uncertainty about whether improvement in LUTS translates to reduced progression or surgery rates.

IPSS Outcomes Across Trials

In the registration trial pool (six placebo-controlled RCTs, N=1,498, 12 weeks), tadalafil 5 mg reduced the International Prostate Symptom Score (IPSS) by a mean of 2.8 points more than placebo (P<0.001) [12]. The minimum clinically important difference for IPSS is 3 points, meaning the mean effect sits just below that threshold; however, roughly 40% of individual patients exceeded 3-point improvement [12]. Uroflowmetry (Qmax) did not improve significantly versus placebo in most trials, which distinguishes tadalafil's mechanism (smooth muscle relaxation via cGMP rather than alpha-1 blockade) from alpha-blockers such as tamsulosin [13].

Combination Therapy with Alpha-Blockers

A 12-week double-blind RCT (N=695) compared tadalafil 5 mg plus tamsulosin 0.4 mg against each agent alone [14]. The combination produced an IPSS reduction of 6.1 points versus 4.5 points for tamsulosin alone and 4.4 points for tadalafil alone (P<0.01 for combination vs. Either monotherapy) [14]. Hypotension rates were not significantly elevated in the combination arm provided tamsulosin was the formulation used, consistent with FDA labeling that permits this combination [11]. GRADE certainty for combination therapy sits at LOW-to-MODERATE due to limited trials beyond 12 weeks.

Comparison with Alpha-Blocker Monotherapy

AUA guidelines on male LUTS (2021 update) give a conditional recommendation for tadalafil 5 mg in men with LUTS and concurrent ED, noting that alpha-blockers produce larger IPSS reductions (mean approximately 4-6 points in equivalent populations) but do not address the erectile dysfunction component [15]. The guideline states: "Tadalafil is recommended as an option for men with LUTS secondary to BPH who also have erectile dysfunction" [15].

Head-to-Head Data: Tadalafil vs. Sildenafil

No large phase III RCT has used erectile function restoration as the primary endpoint in a tadalafil-versus-sildenafil superiority design. The available head-to-head data come from crossover preference studies and network meta-analyses.

Brock et al. 2002 Crossover Study

Brock et al. Enrolled 181 men with ED who had previously responded to sildenafil and randomized them to a crossover of tadalafil 20 mg versus sildenafil 50 mg [6]. The primary outcome was patient preference after four attempts with each drug. Tadalafil was preferred by 71% of participants (P<0.001 vs. 50% null hypothesis) [6]. Secondary outcomes included duration of erection adequate for intercourse, which was numerically longer with tadalafil, though the study was not powered for this endpoint specifically [6]. Risk of bias is moderate: the open-label crossover design and the fact that all participants were already sildenafil-experienced introduce performance and carry-over concerns.

Network Meta-Analysis Data

A 2017 network meta-analysis published in the European Urology database (Choi et al., N=82 RCTs, 19,564 participants) found that all five licensed PDE5 inhibitors produced statistically indistinguishable IIEF-EF improvements at recommended doses, with standardized mean differences ranging from 0.84 to 1.02 versus placebo [4]. Tadalafil's point estimate sat within that range. GRADE certainty for comparative efficacy between PDE5 inhibitors is therefore rated MODERATE (consistent indirect evidence, some risk of bias from industry funding in constituent trials).

Safety Evidence and GRADE Certainty for Harms

Tadalafil's adverse event profile is well-characterized across more than 40 phase III trials and is rated HIGH certainty for common short-term harms and MODERATE certainty for rare or long-term harms.

Common Adverse Effects: Rates from Pooled Data

In pooled placebo-controlled data (N>4,000), the most frequent adverse effects with tadalafil 20 mg were headache (14.5% vs. 5.3% placebo), dyspepsia (12.3% vs. 1.7%), back pain (6.5% vs. 3.3%), myalgia (5.7% vs. 1.9%), and flushing (4.1% vs. 1.2%) [3]. Discontinuation due to adverse effects occurred in 3.1% of tadalafil patients versus 1.5% of placebo patients [3]. Back pain and myalgia are more prominent with tadalafil than with other PDE5 inhibitors, thought to reflect PDE11 inhibition in skeletal muscle [5].

Cardiovascular Safety

The Princeton Consensus III guidelines state that men with stable cardiovascular disease and adequate exercise tolerance (>3-4 METs) can safely use PDE5 inhibitors, including tadalafil [16]. A pooled analysis of cardiovascular events across tadalafil ED trials (N=8,138 patient-exposures) found myocardial infarction rates of 0.37 per 100 patient-years in the tadalafil arm versus 0.84 per 100 patient-years in placebo, a difference that did not reach statistical significance but suggested no elevation in risk [17]. The FDA label carries a black-box warning against concurrent use with nitrates (organic nitrates or nitric oxide donors) due to potentiated hypotension [11].

Vision and Hearing Harms

Post-marketing reports of non-arteritic anterior ischemic optic neuropathy (NAION) led to a label update in 2005. The absolute risk increase remains uncertain; an FDA-requested epidemiological study estimated the background NAION rate in the relevant age group at approximately 2.5 per 100,000 men per year, and case-temporal clustering around PDE5 inhibitor use was weak [18]. GRADE certainty for this harm is LOW given reliance on observational and spontaneous-reporting data.

Guideline Positions and GRADE Alignment

AUA Erectile Dysfunction Guidelines

The 2018 AUA guideline on ED (updated 2024) gives a strong recommendation (consistent with HIGH GRADE certainty) for oral PDE5 inhibitors, including tadalafil, as first-line therapy for ED in the absence of contraindications [19]. The guideline specifically endorses both on-demand and daily dosing as equivalent options for patient selection, stating: "Clinicians should offer PDE5 inhibitors as first-line therapy for men with ED" [19].

EAU Guidelines

The 2024 European Association of Urology guidelines on sexual and reproductive health rate tadalafil as a Grade A recommendation (equivalent to HIGH certainty) for on-demand ED and a Grade B recommendation for daily dosing, noting that while efficacy data are consistent, the optimal duration of continuous daily therapy has not been established in long-term controlled trials [20].

FDA Labeling Summary

The FDA-approved label for tadalafil permits four distinct regimens: 10 mg or 20 mg as needed for ED, 2.5 mg or 5 mg once daily for ED, 5 mg once daily for BPH, and 5 mg once daily for concurrent ED and BPH [11]. No dose adjustment is required for mild-to-moderate hepatic impairment; tadalafil is not recommended in severe hepatic impairment (Child-Pugh C) or in patients on potent CYP3A4 inhibitors without dose reduction to 10 mg maximum per 72 hours [11].

Tadalafil in Special Populations: Evidence Gaps and GRADE Ratings

Diabetes and Cardiovascular Comorbidity

Men with type 2 diabetes have lower baseline PDE5 inhibitor response rates due to autonomic neuropathy and endothelial dysfunction. A subgroup analysis of the pooled registration trials (N=601 diabetic men) showed tadalafil 20 mg produced a successful intercourse rate of 56% versus 23% placebo, an absolute difference of 33 percentage points, somewhat smaller than the 43-point difference seen in non-diabetic men [3]. GRADE certainty within this subgroup is MODERATE (subgroup analysis, no prospective stratified design).

Post-Radical Prostatectomy

A 9-month RCT of daily tadalafil 5 mg starting 4 weeks after nerve-sparing radical prostatectomy (N=423) found that 52% of tadalafil-treated men achieved return of erectile function versus 26% with placebo at 9 months (P<0.001) [10]. A 6-month on-demand arm in the same trial showed 48% return versus 26% placebo [10]. GRADE certainty for post-prostatectomy rehabilitation is MODERATE: the signal is consistent, but this single large trial dominates the evidence base and used varied surgical techniques.

Pulmonary Arterial Hypertension

Tadalafil 40 mg once daily is FDA-approved for pulmonary arterial hypertension (PAH) under the brand name Adcirca (now generic). The PHIRST trial (N=405, 16 weeks) showed a 33-meter improvement in 6-minute walk distance with tadalafil 40 mg versus placebo (P<0.001) [21]. This indication carries a separate HIGH GRADE certainty rating and is outside the ED/BPH scope of this article, but clinicians should be aware of the dose difference (40 mg for PAH vs. 5-20 mg for ED/BPH) when reviewing patient medication lists.

Summary GRADE Table for Tadalafil Indications

| Indication | Dose | GRADE Certainty | Key Effect Size | |---|---|---|---| | On-demand ED | 10-20 mg PRN | HIGH | IIEF-EF +7.9 pts vs placebo | | Daily ED | 5 mg QD | MODERATE | Successful intercourse 64% vs 36% placebo | | BPH/LUTS (monotherapy) | 5 mg QD | MODERATE | IPSS -2.8 pts vs placebo | | BPH + ED (dual indication) | 5 mg QD | MODERATE | Combined endpoint improvement | | Post-prostatectomy rehab | 5 mg QD | MODERATE | Return of EF 52% vs 26% placebo | | PAH (Adcirca) | 40 mg QD | HIGH | 6MWD +33 m vs placebo | | Comparative efficacy vs. Sildenafil | 20 mg vs 50 mg | MODERATE | Patient preference 71% vs 50% null |